1. Home
  2. THAR vs TTNP Comparison

THAR vs TTNP Comparison

Compare THAR & TTNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THAR
  • TTNP
  • Stock Information
  • Founded
  • THAR 2017
  • TTNP 1991
  • Country
  • THAR United States
  • TTNP United States
  • Employees
  • THAR N/A
  • TTNP N/A
  • Industry
  • THAR Biotechnology: Pharmaceutical Preparations
  • TTNP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • THAR Health Care
  • TTNP Health Care
  • Exchange
  • THAR Nasdaq
  • TTNP Nasdaq
  • Market Cap
  • THAR 2.8M
  • TTNP 3.3M
  • IPO Year
  • THAR 2022
  • TTNP 1996
  • Fundamental
  • Price
  • THAR $2.13
  • TTNP $3.53
  • Analyst Decision
  • THAR
  • TTNP
  • Analyst Count
  • THAR 0
  • TTNP 0
  • Target Price
  • THAR N/A
  • TTNP N/A
  • AVG Volume (30 Days)
  • THAR 232.7K
  • TTNP 28.0K
  • Earning Date
  • THAR 11-07-2024
  • TTNP 12-27-2024
  • Dividend Yield
  • THAR N/A
  • TTNP N/A
  • EPS Growth
  • THAR N/A
  • TTNP N/A
  • EPS
  • THAR N/A
  • TTNP N/A
  • Revenue
  • THAR N/A
  • TTNP $3,000.00
  • Revenue This Year
  • THAR N/A
  • TTNP N/A
  • Revenue Next Year
  • THAR N/A
  • TTNP N/A
  • P/E Ratio
  • THAR N/A
  • TTNP N/A
  • Revenue Growth
  • THAR N/A
  • TTNP N/A
  • 52 Week Low
  • THAR $1.84
  • TTNP $3.24
  • 52 Week High
  • THAR $8.55
  • TTNP $14.80
  • Technical
  • Relative Strength Index (RSI)
  • THAR 46.63
  • TTNP 40.85
  • Support Level
  • THAR $2.09
  • TTNP $3.25
  • Resistance Level
  • THAR $2.27
  • TTNP $3.85
  • Average True Range (ATR)
  • THAR 0.17
  • TTNP 0.36
  • MACD
  • THAR -0.00
  • TTNP -0.00
  • Stochastic Oscillator
  • THAR 34.04
  • TTNP 24.76

About THAR Tharimmune Inc.

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

About TTNP Titan Pharmaceuticals Inc.

Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Share on Social Networks: